Keyword: Impax Laboratories

More turnover is coming to Allergan’s board—and this time, it’s the man who arguably built the company.

Teva's EpiPen copy will hit the market even as spot shortages of the ubiquitous auto injector have developed.

Privately held Kaléo has a supply of epinephrine auto injectors and is making sure the public knows its version is available.

India's Aurobindo has submitted a $1.6 billion offer for Novartis' generic dermatology assets in the U.S., according to Livemint.

Retailers settled claims that Impax made an illegal deal to delay its generic version of Solodyn, but insurer and consumer plaintiffs are fighting on.

Amneal CEO Chintu Patel expects to expand a plant in New York and add 400 employees as a merger with Impax nears.

Legend teams with J&J on CAR-T project, Eisai and Biogen's Alzheimer's drug fails in early readout, Impax and Bora Pharma ink deal.

Impax Laboratories will sell its manufacturing site in Taiwan to Bora Pharmaceuticals for $18.5 million and take a charge of up to $80 million.

Ahead of an expected merger, the combined company of Amneal-plus-Impax has a new CEO.

For evidence that a pricing scandal can translate into real lost sales for a pharmaceutical company, look no further than Mylan's third-quarter results.